Neoadjuvant pembrolizumab in locally advanced cutaneous squamous cell carcinoma: multiplex immunofluorescence and bulk RNA sequencing
Single-arm phase II clinical trial (NCT04808999) of neoadjuvant pembrolizumab in patients with PD-1-naive, high-risk resectable cutaneous squamous cell carcinoma. This project hosts the bulk RNA sequencing of the pre-treatment and post-treatment specimens.